On June 20, 2017, Imagion Biosystems President and CEO Bob Proulx provided an update and briefing on the pending Imagion Biosystems initial public offering on the Australian Securities Exchange. An audio recording of the call is now available for listening:
Imagion Biosystems Delivers Major Milestone — IND Application Lodged with U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent
January 31, 2026
Imagion Biosystems Hits Major Milestone, Submits IND Application to U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent Key Highlights: Imagion Biosystems has